Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor α, increase of interleukin 10, and predicted by the initial concentration of interleukin 4
Authors:
- Andreas RadbruchARAndreas Radbruch
Open Access
- 1 April 2000
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 59 (4) , 311-314
Abstract
OBJECTIVE This study was performed to assess whether there is any change in the T cell cytokine pattern in early rheumatoid arthritis (RA) patients treated with methotrexate (MTX) and whether the lymphocytic cytokine pattern correlates with disease activity. METHODS Eight patients with RA (disease duration < six months) were studied serially before, after three, and after six to nine months of treatment with MTX for the cytokines tumour necrosis factor α (TNFα), interferon γ (IFNγ), interleukin 4 (IL4) and interleukin 10 (IL10) by intracellular staining of T cells derived from peripheral blood. Response to treatment was assessed by the modified disease activitiy score. RESULTS The clincial response was accompanied by a significant decrease of TNFα positive CD4+ T cells from a median of 8.53% (interquartile range 5.83–10.91%) before treatment to 6.17% (2.15–6.81%) after six to nine months of treatment (p=0.021). Inversely, IL10 positive T cells increased from a median of 0.65% (interquartile range 0.6–0.93%) to a median of 1.3% (1.22%-1.58%) after six to nine months of treatment (p=0.009). No significant change in the percentage of INFγ positive T cells and a small decrease of IL4 positive T cells during treatment were observed. The percentage of IL4 positive CD4+ T cells before treatment correlated with disease activity after six to nine months (r= −0.7066; p=0.05). CONCLUSIONS During treatment of RA with MTX the percentage of TNFα producing T cells decreases whereas that of IL10 producing T cells increases. This may affect macrophage activation and, therefore, may represent a regulatory mechanism relevant to disease remission. Furthermore, the percentage of IL4 positive CD4+ T cells at disease onset may be a useful prognostic marker.Keywords
This publication has 13 references indexed in Scilit:
- Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppressionClinical and Experimental Immunology, 1999
- Prognostic value of Th1/Th2 ratio in rheumatoid arthritisThe Lancet, 1998
- Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: Evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reactionArthritis & Rheumatism, 1998
- A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitisNature, 1997
- The mechanisms of action of disease-modifying antirheumatic drugs: A review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokinesGeneral Pharmacology: The Vascular System, 1997
- Shift toward T lymphocytes with a T helper 1 cytokine‐secretion profile in the joints of patients with rheumatoid arthritisArthritis & Rheumatism, 1996
- Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen‐induced arthritisEuropean Journal of Immunology, 1996
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Flow cytometric determination of cytokines in activated murine T helper lymphocytes: Expression of interleukin‐10 in interferon‐γ and in interleukin‐4‐expressing cellsEuropean Journal of Immunology, 1994
- Reduction of leukocyte and interleukin‐1β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexateArthritis & Rheumatism, 1993